Stage 2 – Good Manufacturing Practice mRMA Production

MANUFACTURING FACILITY

2,000m² GMP Cleanrooms for Plasmid DNA and mRNA production.

SKILLED WORKFORCE

Creation of 40 new and highly skilled, full time positions.

PRODUCTION CAPACITY

Production of Nucleic acid Cap Analogs for more than 40 million mRNA vaccine doses each month. In-house mRNA vaccine production capability of 8 million doses each month.

TECHNOLOGY CAPABILITY

World-leading ‘GMP vaccine cleanrooms’ facilities, state-of-the-art bioprocessing, chemical process technologies and proprietary manufacturing techniques.

JOBS CREATION

Over 2,000 Australian jobs for people in construction, manufacturing, specialist fields, bio-medical and consulting.

OPERATIONAL TIMEFRAME

Expected operationalisation within 6-months, after Stage 1 – estimated late-October 2022.